Strs Ohio Cassava Sciences Inc Transaction History

Strs Ohio

$24.9 Billion
Q2 2024

A detailed history of Strs Ohio transactions in Cassava Sciences Inc stock. As of the latest transaction made, Strs Ohio holds 11,900 shares of SAVA stock, worth $339,031. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,900

Previous 10,700 11.21%

Holding current value

$339,031

Previous $217,000 32.72%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$12.35 - $26.11 $14,820 - $31,332	1,200 Added 11.21%	11,900 $146,000
Q1 2024 May 13, 2024	SELL	$18.44 - $26.41 $23,972 - $34,333	-1,300 Reduced 10.83%	10,700 $217,000
Q4 2023 Jan 30, 2024	BUY	$12.64 - $30.11 $15,168 - $36,132	1,200 Added 11.11%	12,000 $270,000
Q3 2023 Oct 26, 2023	SELL	$16.64 - $25.32 $31,616 - $48,108	-1,900 Reduced 14.96%	10,800 $179,000
Q2 2023 Jul 31, 2023	BUY	$21.59 - $27.88 $99,314 - $128,248	4,600 Added 56.79%	12,700 $311,000
Q1 2023 Aug 02, 2023	SELL	$23.46 - $36.44 $107,916 - $167,624	-4,600 Reduced 36.22%	8,100 $195,000
Q3 2022 Oct 27, 2022	BUY	$16.33 - $51.06 $9,797 - $30,636	600 Added 8.0%	8,100 $338,000
Q2 2022 Jul 25, 2022	BUY	$17.22 - $38.47 $6,888 - $15,388	400 Added 5.63%	7,500 $210,000
Q1 2022 Apr 21, 2022	BUY	$32.6 - $53.05 $127,140 - $206,895	3,900 Added 121.88%	7,100 $263,000
Q4 2021 Jan 24, 2022	SELL	$36.77 - $90.91 $187,527 - $463,641	-5,100 Reduced 61.45%	3,200 $139,000
Q2 2021 Jul 26, 2021	BUY	$32.15 - $89.72 $225,050 - $628,040	7,000 Added 538.46%	8,300 $709,000
Q1 2021 Apr 23, 2021	BUY	$7.09 - $87.95 $9,217 - $114,335	1,300 New	1,300 $58,000

Others Institutions Holding SAVA

# of Institutions

184

Shares Held

13.3M

Call Options Held

1.38M

Put Options Held

2.04M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.14B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account